Neuronetics, Inc. STIM R2K

Healthcare · Medical Devices · United States

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Market & Price

Market Cap

$107.17M

Current Price

$1.54

High / Low (52W)

$4.66 / $1.18

Beta

1.13

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$0.19

Price to Book

8.06

P/S

0.71

EV/EBITDA

-7.10

Dividend Yield

Profitability & Returns

ROCE

-28.39%

ROE

-131.56%

ROA

-13.56%

Profit Margin

-24.48%

Op Margin

-26.11%

EPS (Latest Qtr)

$-0.16

EPS (TTM)

$-0.54

Balance Sheet & Liquidity

Debt/Equity

5.01

Quick Ratio

1.03

Current Ratio

1.67

Debt

$85.39M

Total Assets

$141.55M

Current Assets

$61.55M

Working Capital

$31.03M

Ownership

Promoter Holding

32.19%

Chg in Prom Hold

FII / Inst Holding

59.86%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$183.13M

Total Revenue (TTM)

$151.64M

EBITDA

$-25.78M

Free Cash Flow

$-4.58M

Operating Cash Flow

$-12.80M

Shares Outstanding

69.59M

Gross Margin

48.22%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

31.76%

Profit 5Y

-1.65%

Revenue (YoY)

7.80%

Earnings (YoY)

PROS

Compounding revenue at 31.8% over 5 years.

CONS

Earnings shrank at -1.6% CAGR over 5 years.
Trading 67.0% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	STIM Neuronetics, Inc. R2K	1.54	-	$107.17M	-	-28.39%	-131.56%	31.76%	-1.65%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	10.15M	13.25M	13.74M	-	12.73M	16.57M	16.00M	-	11.48M	9.74M	12.45M	-	12.29M	14.20M	13.80M	14.18M	16.33M	16.50M	15.54M	17.61M	17.88M	17.42M	16.45M	-	-	31.98M	38.11M	37.30M	41.78M	34.45M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16.24M	20.35M	20.19M	20.07M	18.30M
Gross Profit	5.99M	7.81M	7.86M	9.15M	7.70M	10.01M	10.70M	11.92M	9.92M	12.40M	11.81M	13.14M	8.66M	7.42M	9.79M	11.82M	10.07M	11.45M	10.65M	10.70M	12.29M	12.93M	11.40M	12.77M	11.76M	13.09M	12.18M	-	-	15.74M	17.76M	17.11M	21.70M	16.15M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26.75M	25.82M	24.43M	26.75M	25.15M
Operating Income	-3.99M	-2.58M	-2.81M	-4.23M	-4.61M	-5.24M	-4.33M	-5.66M	-7.06M	-6.61M	-6.33M	-6.94M	-10.37M	-6.86M	-2.42M	-2.66M	-6.91M	-6.56M	-7.18M	-10.13M	-9.80M	-7.45M	-9.91M	-7.35M	-8.87M	-6.86M	-8.51M	-	-	-11.01M	-8.06M	-7.32M	-5.04M	-8.99M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-10.06M	-7.17M	-6.51M	-4.32M	-8.07M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.70M	1.80M	2.00M	2.10M	2.00M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12.67M	-9.87M	-9.39M	-7.19M	-10.81M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-4.51M	-2.87M	-3.75M	-4.92M	-5.50M	-7.50M	-4.96M	-6.14M	-7.53M	-7.09M	-6.87M	-7.55M	-12.61M	-7.76M	-3.42M	-3.66M	-7.88M	-7.53M	-8.15M	-10.84M	-10.42M	-7.61M	-10.52M	-4.90M	-9.39M	-7.87M	-9.83M	-	-	-12.68M	-10.12M	-9.04M	-7.16M	-10.79M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.41	-0.18	-	-0.31	-0.29	-0.31	-0.41	-0.39	-0.28	-0.38	-0.17	-0.33	-0.27	-0.33	-	-	-0.21	-0.15	-0.13	-0.10	-0.16
R&D Expense	2.03M	2.15M	1.84M	1.92M	1.55M	2.33M	2.12M	2.22M	2.79M	3.22M	3.49M	4.25M	3.02M	2.12M	1.95M	2.11M	2.31M	2.29M	1.57M	1.80M	2.04M	2.35M	2.79M	2.36M	2.15M	2.35M	2.23M	2.42M	-	1.62M	1.80M	1.50M	-	1.36M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	40.43M	52.78M	62.66M	49.24M	-	65.21M	71.35M	74.89M	149.16M
Cost of Revenue	-	-	-	-	-	-	15.48M	19.64M	20.73M	76.85M
Gross Profit	27.61M	30.80M	40.33M	47.27M	37.69M	-	49.72M	51.70M	54.16M	72.31M
Operating Expenses	-	-	-	-	-	-	84.83M	82.26M	88.72M	103.74M
Operating Income	-9.34M	-13.61M	-19.83M	-26.93M	-22.31M	-	-35.11M	-30.55M	-34.56M	-31.44M
EBITDA	-	-	-	-	-	-	-31.96M	-23.36M	-35.17M	-28.05M
Interest Expense	-	-	-	-	-	-	3.60M	4.80M	6.50M	7.60M
Pretax Income	-	-	-	-	-	-	-37.21M	-30.16M	-43.74M	-39.12M
Tax Provision	-	-	-	-	-	-	-	-	-	-
Net Income	-11.23M	-16.06M	-24.10M	-29.04M	-27.45M	-	-37.16M	-30.19M	-43.71M	-39.00M
Diluted EPS	-	-	-	-1.58	-1.46	-1.22	-1.38	-1.05	-1.37	-
R&D Expense	8.22M	7.94M	8.23M	13.75M	9.20M	7.92M	9.34M	9.52M	12.77M	6.58M

Compounded Sales Growth

5 Years:	31.76%
1 Year:	7.80%

Compounded Profit Growth

5 Years:	-1.65%
1 Year:	-

Stock Price Performance

1 Year:	-60.61%
6 Months:	+12.41%
3 Months:	+14.93%
1 Month:	-9.41%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	38.94M	117.02M	100.17M	78.66M	-	116.88M	115.83M	140.90M	141.55M
Current Assets	-	-	-	-	-	-	-	98.77M	93.79M	58.12M	61.55M
Cash & Equivalents	-	-	29.15M	104.58M	75.71M	48.96M	-	70.34M	59.68M	18.46M	28.13M
Inventory	-	-	-	-	-	-	-	8.90M	8.09M	4.25M	4.33M
Receivables	-	-	-	-	-	-	-	13.59M	15.78M	23.36M	16.47M
Total Liabilities	-	-	44.45M	45.98M	52.32M	53.16M	-	59.82M	81.64M	109.10M	115.31M
Current Liabilities	-	-	11.99M	13.56M	27.69M	13.68M	-	33.20M	19.81M	31.27M	30.52M
Long Term Debt	-	-	29.56M	30.39M	19.90M	34.62M	-	22.83M	59.28M	55.15M	65.81M
Total Debt	-	-	-	-	-	-	-	39.74M	62.47M	82.63M	90.30M
Total Equity	-166.12M	-177.12M	-192.65M	71.04M	47.85M	25.49M	-	57.06M	34.19M	27.71M	22.38M
Shares Outstanding	-	-	-	-	-	-	-	27.27M	29.09M	55.68M	68.99M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-8.54M	-11.14M	-20.59M	-30.48M	-28.39M	-	-30.74M	-32.04M	-31.00M	-20.37M
Investing Cash Flow	-324.00K	-594.00K	-1.01M	-813.00K	-730.00K	-	6.73M	-1.32M	-2.41M	-801.00K
Financing Cash Flow	4.90M	23.84M	97.04M	2.42M	2.37M	-	207.00K	22.70M	-6.81M	35.85M
Capital Expenditure	-	-	-	-	-	-	-3.27M	-2.37M	-1.47M	-801.00K
Free Cash Flow	-	-	-	-	-	-	-34.01M	-34.41M	-32.46M	-21.18M
Net Change in Cash	-	-	-	-	-	-	-23.80M	-10.66M	-40.22M	14.68M

Ratios (Annual)

Figures in %.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	76.2%	76.4%	75.4%	76.5%	-	76.3%	72.5%	72.3%	48.5%
Operating Margin %	-	-33.7%	-37.6%	-43.0%	-45.3%	-	-53.8%	-42.8%	-46.2%	-21.1%
Net Margin %	-	-39.7%	-45.7%	-46.4%	-55.7%	-	-57.0%	-42.3%	-58.4%	-26.1%
ROE %	6.3%	8.3%	-33.9%	-60.7%	-107.7%	-	-65.1%	-88.3%	-157.8%	-174.3%
ROCE %	-	-50.5%	-19.2%	-37.2%	-34.3%	-	-42.0%	-31.8%	-31.5%	-28.3%

Shareholding Pattern

Insiders

32.19%

Institutions

59.86%

Public Float

88.28%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Madryn Asset Management, LP	26.55%	18.48M	$28.45M
2	UBS Group AG	4.13%	2.87M	$4.42M
3	Balyasny Asset Management LP	3.94%	2.74M	$4.23M
4	Blackrock Inc.	3.33%	2.32M	$3.57M
5	Vanguard Capital Management LLC	2.94%	2.05M	$3.15M
6	Lane Generational LLC	2.55%	1.77M	$2.73M
7	FourWorld Capital Management, LLC	2.14%	1.49M	$2.29M
8	Masters Capital Management, LLC	1.44%	1.00M	$1.54M
9	Geode Capital Management, LLC	1.38%	958.99K	$1.48M
10	State Street Corporation	1.21%	842.55K	$1.30M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for STIM

No recent headlines available.

STIM · Healthcare

Neuronetics, Inc.

About

Key Facts

Sector	Healthcare
Industry	Medical Devices
Headquarters	United States
Employees	658
Website	https://neurostar.com/neuronetics

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Neuronetics, Inc. STIM R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More